Fig. 2
From: In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment
Comparative single dose PK profiles of PAT101 and pegloticase in TG mice. After intravenous injection of PAT101 (n = 5) or pegloticase (n = 5) into TG mice, the residual PAT101 and pegloticase in plasma were measured using enzymatic activity assay at indicated time points (0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240, and 336 hr after administration). The uricase molar concentration of the injected test substances is the same. The calculated plasma uricase activity (mU/mL) in log scale was plotted against time (hr) to examine the PK profiles. The values of PK parameters, half-life and AUC, are shown as mean ± SD